In Vitro Evaluation of Therapeutic Antibodies Against a SARS-CoV-2 Omicron B.1.1.529 Isolate

Overview

Journal Sci Rep

Specialty Science

Date 2022 Mar 19

PMID 35304531

Authors

Franck Touret

Cecile Baronti

Hawa Sophia Bouzidi

Xavier de Lamballerie

Affiliations

Soon will be listed here.

Abstract

The emergence and rapid spread of the Omicron variant of SARS-CoV-2, which has more than 30 substitutions in the spike glycoprotein, compromises the efficacy of currently available vaccines and therapeutic antibodies. Using a clinical strain of the Omicron variant, we analyzed the neutralizing power of eight currently used monoclonal antibodies compared to the ancestral B.1 BavPat1 D614G strain. We observed that six of these antibodies have lost their ability to neutralize the Omicron variant. Of the antibodies still having neutralizing activity, Sotrovimab/Vir-7831 shows the smallest reduction in activity, with a factor change of 3.1. Cilgavimab/AZD1061 alone shows a reduction in efficacy of 15.8, resulting in a significant loss of activity for the Evusheld cocktail (42.6-fold reduction) in which the other antibody, Tixagevimab, does not retain significant activity against Omicron. Our results suggest that the clinical efficacy of the initially proposed doses should be rapidly evaluated and the possible need to modify doses or propose combination therapies should be considered.

Citing Articles

SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.

Hoechstetter M, Hollwich E, Illner D, Pham T, von Bergwelt-Baildon M, Dreyling M Eur J Haematol. 2025; 114(4):690-699.

PMID: 39757858 PMC: 11880995. DOI: 10.1111/ejh.14377.

Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection.

Tai L, Yeh C, Chang Y, Liu J, Hsu K, Cheng J Int J Mol Sci. 2024; 25(11).

PMID: 38892294 PMC: 11172837. DOI: 10.3390/ijms25116105.

Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis.

Amani B, Amani B Immun Inflamm Dis. 2024; 12(4):e1262.

PMID: 38652021 PMC: 11037253. DOI: 10.1002/iid3.1262.

Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study.

Hwang S, Lee N, Nam E, Kim Y, Kim S, Chang H Infect Dis Ther. 2024; 13(5):1037-1050.

PMID: 38607524 PMC: 11098974. DOI: 10.1007/s40121-024-00971-w.

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?.

Gidari A, Sabbatini S, Bastianelli S, Pierucci S, Busti C, Svizzeretto E Viruses. 2024; 16(3).

PMID: 38543720 PMC: 10975286. DOI: 10.3390/v16030354.

References

Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603(7902):679-686. PMC: 8942855. DOI: 10.1038/s41586-022-04411-y. View

Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View

Kim C, Ryu D, Lee J, Kim Y, Seo J, Kim Y . A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun. 2021; 12(1):288. PMC: 7803729. DOI: 10.1038/s41467-020-20602-5. View

Liu C, Ginn H, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A . Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021; 184(16):4220-4236.e13. PMC: 8218332. DOI: 10.1016/j.cell.2021.06.020. View

VanBlargan L, Errico J, Halfmann P, Zost S, Crowe Jr J, Purcell L . An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022; 28(3):490-495. PMC: 8767531. DOI: 10.1038/s41591-021-01678-y. View

Malani A, LaVasseur B, Fair J, Domeier R, Vershum R, Fowler R . Administration of Monoclonal Antibody for COVID-19 in Patient Homes. JAMA Netw Open. 2021; 4(10):e2129388. PMC: 8517740. DOI: 10.1001/jamanetworkopen.2021.29388. View

Jones B, Brown-Augsburger P, Corbett K, Westendorf K, Davies J, Cujec T . The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021; 13(593). PMC: 8284311. DOI: 10.1126/scitranslmed.abf1906. View

Dong J, Zost S, Greaney A, Starr T, Dingens A, Chen E . Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol. 2021; 6(10):1233-1244. PMC: 8543371. DOI: 10.1038/s41564-021-00972-2. View

Touret F, Gilles M, Barral K, Nougairede A, van Helden J, Decroly E . In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020; 10(1):13093. PMC: 7403393. DOI: 10.1038/s41598-020-70143-6. View

10.

Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer A, Ginn H . Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021; 184(11):2939-2954.e9. PMC: 8008340. DOI: 10.1016/j.cell.2021.03.055. View

11.

Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N . Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021; 26(24). PMC: 8212592. DOI: 10.2807/1560-7917.ES.2021.26.24.2100509. View

12.

Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G . Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020; 11(1):4682. PMC: 7499305. DOI: 10.1038/s41467-020-18463-z. View

13.

Starr T, Greaney A, Addetia A, Hannon W, Choudhary M, Dingens A . Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021; 371(6531):850-854. PMC: 7963219. DOI: 10.1126/science.abf9302. View

14.

Liu Y, Liu J, Plante K, Plante J, Xie X, Zhang X . The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature. 2021; 602(7896):294-299. PMC: 8900207. DOI: 10.1038/s41586-021-04245-0. View

15.

Pinto D, Park Y, Beltramello M, Walls A, Tortorici M, Bianchi S . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815):290-295. DOI: 10.1038/s41586-020-2349-y. View

16.

Cameroni E, Bowen J, Rosen L, Saliba C, Zepeda S, Culap K . Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022; 602(7898):664-670. PMC: 9531318. DOI: 10.1038/s41586-021-04386-2. View

17.

Taylor P, Adams A, Hufford M, de la Torre I, Winthrop K, Gottlieb R . Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021; 21(6):382-393. PMC: 8054133. DOI: 10.1038/s41577-021-00542-x. View

18.

Kumar S, Thambiraja T, Karuppanan K, Subramaniam G . Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol. 2021; 94(4):1641-1649. DOI: 10.1002/jmv.27526. View

19.

Touret F, Driouich J, Cochin M, Petit P, Gilles M, Barthelemy K . Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. Antiviral Res. 2021; 193:105137. PMC: 8274277. DOI: 10.1016/j.antiviral.2021.105137. View

20.

Kaptein S, Goethals O, Kiemel D, Marchand A, Kesteleyn B, Bonfanti J . Publisher Correction: A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. Nature. 2021; 599(7883):E2. DOI: 10.1038/s41586-021-04123-9. View